Home › Funds › Balyasny Asset Management › ABUS
Balyasny Asset Management position in ABUS
ARBUTUS BIOPHARMA CORP · Health Care
Latest position (Q1 2026)125.52K sh
Reported value held$564.85K
Portfolio Weight0.00%
First reportedQ3 2022
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2022 | 12.25K | $23.00K | New |
| Q4 2022 | 14.63K | $34.09K | Add |
| Q4 2024 | 41.69K | $136.33K | New |
| Q1 2025 | 18.92K | $66.02K | Reduce |
| Q3 2025 | 107.67K | $488.80K | New |
| Q4 2025 | 141.65K | $681.32K | Add |
| Q1 2026 | 125.52K | $564.85K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding ABUS
- Morgan Stanley 17.70M sh · $84.95M · Q2 2026
- BlackRock Inc 13.77M sh · $66.08M · Q2 2026
- Vanguard Group 9.24M sh · $44.46M · Q4 2025
- Geode Capital Management 4.12M sh · $19.77M · Q2 2026
- Goldman Sachs Group 3.51M sh · $16.83M · Q2 2026
- Bank of America Corp 2.65M sh · $12.70M · Q2 2026
- Legal & General Investment Management America 2.47M sh · $11.84M · Q2 2026
- Charles Schwab Investment Management 1.43M sh · $6.87M · Q2 2026
- Northern Trust Corp 1.42M sh · $6.81M · Q2 2026
- Citigroup Inc 879.24K sh · $4.22M · Q2 2026
- Arrowstreet Capital 650.70K sh · $3.12M · Q2 2026
- Wellington Management Group 461.65K sh · $2.22M · Q2 2026